Veklury® Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations Pharmaceutical Investing
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023 Pharmaceutical Investing
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27 Pharmaceutical Investing
FDA Accepts Application for Merck's KEYTRUDA® Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Pharmaceutical Investing
AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year Pharmaceutical Investing
Gilead Sciences: 4 Questions: Global Experts Convene To Identify Key Measures to Long-Term Success in HIV Pharmaceutical Investing
EMD Electronics Expands Semiconductor Manufacturing Capacities for the World's Largest Integrated Specialty Gases Facility in Hometown, Pennsylvania Life Science Investing News
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office Pharmaceutical Investing
